15th Sep 2015 13:19
LONDON (Alliance News) - GW Pharmaceuticals PLC Tuesday said it received positive top line results from its Phase 2a placebo-controlled clinical trial of cannabidiol in patients with schizophrenia.
Shares in GW were trading up 12% at 629.00 pence Tuesday afternoon.
The biopharmaceutical company said that the 88 patients involved in the trial had previously failed to respond adequately to first line anti-psychotic medications.
In the trial using cannabidiol, which is a cannabinoid, or compound found in cannabis, GW found that it was consistently superior to placebo, and that the proportion of responders was higher than that of participants on placebo.
GW added that the safety profile of cannabidiol was "reassuring", with no serious adverse events and an overall frequency of adverse events very similar to placebo.
"These findings further reinforce the potential role of cannabinoids in the field of neuropsychiatric disease," stated Justin Gover, GW's chief executive officer. "We believe that the signals of efficacy demonstrated in this trial, together with a notably reassuring safety profile, provide GW with the prospect of new and distinct cannabinoid neuropsychiatric product pipeline opportunity," he added.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L